Why the study?
Do GLP-1 receptor agonists reduce antipsychotic-associated body weight gain in patients with schizophrenia compared to controls?
Do GLP-1 receptor agonists reduce antipsychotic-associated body weight gain in patients with schizophrenia compared to controls?
GLP-1 receptor agonists significantly reduce antipsychotic-associated body weight gain and improve cardio-metabolic risk factors in patients with schizophrenia, particularly those treated with clozapine or olanzapine.
No takes yet. Share an insight, caveat, or question.
GLP-1RAs merit consideration to limit antipsychotic weight gain in schizophrenia; extends efficacy data to clozapine/olanzapine-treated patients.
Siskind et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: